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Nutrition in paediatric Crohn’s disease
Crohn’s disease CD manifests during childhood or adolescence. 
Protein-energy malnutrition (PEM) is a frequent consequence of 
CD.1–3 PEM in childhood and adolescence leads to failure to thrive 
and deficit in final height. According to different studies and to 
diagnosis delays, linear growth is reduced in one to two third of 
affected children at the time of diagnosis. However, comparison 
between populations is difficult because the definition of growth 
retardation varies according to different studies.1–3 Protracted PEM 
with subsequent failure to thrive is associated with an impairment in 
the achievement of the final target size. In addition, protracted use of 
steroids and/or insufficient control of the disease activity may further 
impair growth and body composition.
Primary therapy for CD, has two aims, namely i) the control of 
the inflammatory process, as assessed by the the paediatric 
Crohn’s disease activity index (PCDAI) as well as ii) the correction 
or the prevention of malnutrition and failure to thrive. One of the 
“peculiarities” of CD is the ability of nutritional therapy to achieve 
both of them. Growth is fundamental to the practice of paediatrics, 
so by taking growth as the primary outcome measure in this chronic 
inflammatory disease, an important issue is addressed for the 
patients and their families as well as for paediatricians.
Factors inducing malnutrition and failure to thrive
Several associated factors are responsible for PEM, including 
poor oral intake, intestinal malabsorption, increased gut losses 
from protein losing enteropathy, increased nutrient requirements, 
increased protein turn over, and drug nutrient interactions (Table I).4–11 
Energy and protein substrates are diverted into the inflammatory 
process, thus weight loss, and linear growth as well as pubertal 
development in children are notably retarded. There is considerable 
controversy about nutritional needs during phases of active and 
inactive disease. It is, for example, often assumed that in acute 
illness a child requires increased nutritional support, however the 
precise relationship between illness severity and energy expenditure 
is uncertain. Measurement of resting energy expenditure (REE) and 
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its relationship with disease activity in children with inflammatory 
bowel disease has provided conflicting results.6–9
Macrophage products such as Tumour Necrosis Factor-α (TNF-α) 
and interleukins 1 and 6 may be the central molecules that link 
the inflammatory process to derangements of homeostasis.12,13 An 
association between impaired growth in children with CD and low 
IGF-I levels is well recognised. Early studies emphasised the role 
of malnutrition in the suppression of IGF-I production. Insulin-like 
growth factor I (IGF-I), produced by the liver in response to growth 
hormone (GH) stimulation, is the key mediator of GH effects at the 
growth plate of bones.14 However, a simple nutritional hypothesis 
fails to explain all the observations related to growth in children 
with CD. The direct, growth-inhibitory effects of pro-inflammatory 
cytokines are increasingly being recognised and explored. In rats 
with trinitrobenzenesulphonic acid-induced colitis, 40% of growth 
impairment was attributable to inflammation, with the rest being due 
to undernutrition.15 In transgenic mice without inflammation, raised 
IL-6 retards growth and suppressing insulin-like growth factor 
(IGF)-I.16 
Steroid dependency and their side effects when used for a long 
period, justify the need to limit their use. The permanent height 
deficit documented in children with CD seems to be directly linked to 
the duration of steroid treatment and to the age of diagnosis or the 
localisation of the disease.17,18 Whatever the consequences on the 
final height, which vary from one study to another, the consideration 
of the quality of the bone mineralisation has now become of a 
greater concern in relation to both the degree and the persistence of 
inflammation as well as the long-term use of steroids.19 
Enteral feeding
CD is associated with frequent nutritional deficiencies, the pattern 
and severity of which depends on the extent, duration and activity 
of the inflammation. Nutritional support allows these deficiencies in 
energy, macro- and micro-nutrients to be corrected. Enteral feeding 
(EF) is a primary therapy for CD, as it allows the inflammatory activity 
to be controlled and the patient to be kept in remission. Nutritional 
support is especially important in childhood CD as an alternative 
to pharmacological treatment, especially steroids. O’Morain et al 
were the first to perform a controlled study in acute CD showing 
that EF based on an elemental diet was as effective as steroids, 
with remission rates of 81 and 80%, respectively.20 Subsequent 
prospective controlled trials have confirmed the therapeutic efficacy 
of EF, even if the published meta-analyses of EF as primary therapy 
in CD reported only a modest advantage for steroids.21–24 However, 
the value of nutritional support in the correction and maintenance of 
nutritional status is widely accepted.25
Enteral feeding (EF) has been traditionally proposed in the proximal 
localisation of the disease where its efficacy has been documented. 
However, many cases with disease involving the colon have been 
reported.26,27 The therapeutic effect of EF is multifactorial (Table II). 
Whether or not the type of enteral feeds is elemental, oligopeptides 
(protein hydrolysate) or whole protein may influence the result of 
EF still remains the subject of debate.28,29 Intriguingly, there is also 
increasing evidence that an aggressive nutritional programme may 
in itself be sufficient to reduce the mucosal inflammatory response. 
EF alone may reduce many pro-inflammatory cytokines to normal, 
and allow mucosal healing.30,31 In addition, specific nutritional 
components, such as n-3 polyunsaturated fatty acids, may have an 
anti-inflammatory effect as they may alter the pattern of leukotrienes 
generated during the immune response.32 Several other factors have 
also been thought to determine the response to EF (Table II). Recent 
studies have emphasised the role of anti-inflammatory cytokine 
such as transforming growth factor-beta (TGFb) present in the diet. 
A polymeric diet (Modulen IBD®, Nestlé®) rich in tTGFb2 is now 
widely used as a single nutrient and has been shown to induce 
remission in children with active CD.33 We have recently reported 
the beneficial effects of this diet in children regardless of the route of 
administration orally or by gastric tube feeding.34 Moreover, Lionetti 
et al studied intestinal microbiota in children receiving full EF using 
Modulen IBD® for 8 weeks.35 In 8 out of 9 children, the exclusive EF 
alone induced disease remission. In 1 child, steroids were added to 
achieve remission. In all children, analysis of gel band distribution 
revealed profound modification of the intestinal microbiota after 
exclusive EF. These data suggest that a possible mechanism of 
action of EF in inducing disease remission in CD is the capacity 
of modification of intestinal microbiota. Possible explanations of 
such capacity are both low residue and prebiotic properties of the 
polymeric liquid formula. In another study, exclusive EF was shown 
to reduce bacterial diversity and to initiate a sustained modulation 
of all predominant intestinal bacterial groups.36 Exclusive EF may 
reduce inflammation through modulating intestinal Bacteroides 
species. The implications of these results for exclusive EF therapy 
and CD pathogenesis has became an important area of research. 
Phenotype as well as genotype of the disease have been thought 
to influence the response to EF. Buchanan et al reported an 8-week 
course of primary exclusive EF in 114 children, median age at 
diagnosis was 11.6 years.37 Disease phenotype was assigned using 
published classifications. Inflammatory markers and anthropometry 
(Z-scores) were calculated before and after treatment. Fifty-seven 
children (51.8%) were fed orally whilst 53 (48.2%) were fed by tube. 
Eighty-eight children (80%) achieved remission. Patients in remission 
had comparative improvements in weight and BMI Z-scores by 
the end of treatment. Individuals with isolated terminal ileal disease 
(N = 4) had lower remission rates than children in whom CD affected 
other locations (P = 0.02). No other significant differences in remission 
rates for any other disease locations were found. The authors 
concluded that EF nutrition induced clinical remission, normalisation 
of inflammatory markers and improved weight/BMI Z-scores in most 
patients. This study demonstrated that disease phenotype should not 
influence clinicians when commencing patients on exclusive EF.37 
Table II: Mode of action of enteral feeding in Crohn’s disease
- Bowel rest
- Reduced intestinal secretions
- Low antigenic load
- Decreased intestinal permeability
- Anti-inflammatory effect of diet (transforming growth factor-beta (TGFb2)
- Modification of intestinal microbiota
- Trophic nutrients
- Improved nutritional status
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It has also been recently reported that the response to treatment 
with systemic steroids, AZA/6-MP and infliximab are not related to 
NOD2/CARD15 mutations, age of diagnosis and disease behaviour. 
Patients with colonic disease seem to have higher rates of steroid 
dependency.38
Although the totality of the evidence is not consistent, available data 
suggest that EF may be useful for maintaining remission in patients 
with CD. Large randomised controlled trials are necessary to assess 
definitively the efficacy of EF in the maintenance of CD remission.39
Parenteral nutrition
In the early 1970s, it was postulated that “bowel rest” achieved by 
the administration of parenteral nutrition (PN) might be of primary 
importance in the treatment of CD. Many trials since then examined 
this theory, but the results were difficult to interpret because of 
major methodological flaws. Greenberg et al achieved a prospective, 
controlled trial to compare directly the efficacy of TPN with continuous 
EF as a primary therapy in patients with CD40 and found similar short 
term remission rates and long-term outcomes in patients receiving 
either treatment.41–43
The role of intraluminal nutrients and the preservation of the intestinal 
mucosal barrier function seems very important and makes the use 
of TPN questionable. Thus, TPN can no longer be regarded as having 
a role in the primary treatment of active uncomplicated CD. Its use 
in complicated disease remains, but probably in an adjunctive rather 
than a therapeutic role (Table III).
Immunosuppressive therapies influencing growth
Early forms of CD in children are usually severe because of the 
diagnostic challenges, the extent of the lesions and CD’s duration. 
In the adolescent or the young adult it is now possible to predict 
the outcome of the disease based on the extent and severity of the 
lesions at the time of the first CD episode. 44 CD can be considered 
to be a lifetime disease with a major risk of extension and growth 
impairment. Childhood CD therefore requires a therapeutic approach, 
even more so when discovered early, which aims to limit long-term 
use of steroids and surgery. In a long term therapeutic strategy CD 
cases in very young children might justify the wider and earlier use of 
immunosuppressive drugs such as azathioprine, 6-mercaptopurine 
or methotrexate in view of the documented efficacy of these drugs in 
maintaining remission in serious and/or steroid dependent CD cases 
in adults as well as in children.45–48
The efficacy of infliximab as maintenance therapy in patients 
with otherwise chronically active CD is well established. Data 
concerning linear catch up growth following anti-TNF therapy are 
now available. In a cohort of 32 children and adolescents (63% 
males; mean age 13.4 years, range 4.7–17.3) with chronically active 
CD, despite immunomodulatory and prior corticosteroid therapy, 
were commenced on infliximab therapy. 49 Growth parameters 
standardised for age, gender, and pubertal development prior to and 
following infliximab therapy were compared. In all, 28 of 32 patients 
tolerated and responded to the induction regimen and 27 responders 
continued to receive infliximab via regularly scheduled infusions 
(n = 22) or episodically (n = 5) for a median of 26 months. Mean 
standard deviation score (SDS) for height at the time of initiation of 
infliximab therapy was -1.15 +/- 1.2 and had declined despite the use 
of other therapies from -0.44 +/- 1.1 at initial diagnosis. Increases in 
height velocity and stature during infliximab therapy were limited by 
pubertal stage: Tanner I-III: DeltaSDS for height velocity was +3.94, 
for height +/-0.50, (P < 0.001); Tanner IV, V: DeltaSDS for height 
velocity +0.22, for height +/- 0.02, (P = NS). The authors concluded 
that height velocity improved and height centile increased during 
infliximab therapy provided patients were treated prior to or in early 
puberty. These data support the use of infliximab in young patients 
with otherwise refractory disease, and suggest that ultimate height 
in this subset of children with severe CD may be less compromised 
than with previous therapies.49 A recent prospective study involved 
176 children (mean age 10.1 years; 65% male) younger than 
16 years old at diagnosis and Tanner I to III during the study. They 
had mild (33%) or moderate/severe (67%) disease at diagnosis. 50 
Clinical and growth data were prospectively obtained during the study. 
First-year treatments included immunomodulators (60%), 
corticosteroids (77%), 5-aminosalicylates (61%), anti-TNF (15%), 
and EF (10%).Disease activity at one year was inactive/mild 
(89%) or moderate/severe (11%). By two years, 86% had received 
immunomodulators and 36% anti-TNF. Mean height Z-scores at 
diagnosis, one year, and two years were -0.49 +/- 1.2 standard 
deviations (SDs), -0.50 +/- 1.2, and -0.46 +/- 1.1, respectively. 
Of the subjects, 10%, 8%, and 6.5% had height Z-scores less than 
-2 SD at diagnosis and 1 year, and 2 years of treatment respsectively. 
A height velocity Z-score less than -1SD was seen in 45% of subjects 
at one year and 38% at two years. The mean height velocity Z-score, 
however, increased between one and two years from -0.71 to 0.26 
(P < 0.03). Duration of corticosteroid use longer than six months 
in the first year of treatment was associated with abnormal height 
velocity at one year. Interestingly, no statistically significant effect on 
height velocity Z-scores was noted when comparing those receiving 
or not receiving infliximab. The persistent growth delay despite 
improved disease activity and the frequent use of immunomodulators 
and biologics suggests that additional strategies are needed to 
improve growth outcomes. Although surgery has been shown to 
improve growth velocity, it does not prevent relapse.51 Thus surgery 
should be used only in refractory and limited CD resistant to anti-TNF 
treatment.
Introduction of rhGH therapy in children was associated with 
a cessation in the deterioration in linear growth. However, an 
improvement in height SDS was not observed over the period of the 
study.52 Future studies should explore the efficacy of a higher dose 
of rhGH in CD. Because of the unfavourable cost and side effects of 
rhGH considerations, it is now probably preferable to avoid long term 
steroid treatment and/or to use nutritional therapy whose efficacy 
has been documented in children.53
Table III: Indications for parenteral nutrition
- Severe fulminant enterocolitis




- Severe anoperineal disease
- Perioperative management
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Conclusions
The severity and course of the cases diagnosed before the age of 
10 must be taken into account in the therapeutic strategy. Current 
treatment regimens limit the use of corticosteroids, by using 
immunomodulatory drugs, recommend the use of enteral nutrition, 
and, if necessary, and consider surgery for intestinal complications 
of localised CD. Biologic agents with the potential for mucosal 
healing hold promise of growth enhancement even among children 
whose growth remained compromised with previously available 
therapies. Treatments, such as anti-TNF, are now becoming more 
widely used and may offer advantages in promoting growth. There 
remains, however, a need for large, multi centre studies of the 
different treatment options in paediatric CD. One should emphasise 
the importance of using standardised measurements of growth, 
such as height velocity standard deviation scores and height 
standard deviation scores as outcome measures to monitor progress 
in response to treatment. For all treatment modalities, there is a 
window of opportunity to achieve normal growth before puberty is 
too advanced.
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